Systemic Lupus Erythematosus (SLE) Therapy: The Old and the New

Area of Science:

• Rheumatology
• Immunology
• Pharmacology

Background:

• Systemic lupus erythematosus (SLE) remains a chronic autoimmune disease associated with significant morbidity, mortality, and reduced quality of life due to disease activity, comorbidities, and treatment toxicity.
• Residual symptoms like fatigue persist even in lupus remission, impacting patients' daily lives.
• Current SLE treatment paradigms have advanced from conventional immunosuppressants to targeted biologic agents, with belimumab being the first approved for SLE.

Purpose of the Study:

• To provide a comprehensive overview of current and emerging therapeutic strategies for managing systemic lupus erythematosus (SLE).
• To highlight the integration of pharmacological and non-pharmacological approaches in SLE treatment.
• To discuss novel therapies targeting specific immune pathways involved in SLE pathogenesis.

Main Methods:

• Literature review of current pharmacological treatments for SLE, including conventional immunosuppressants and biologic agents.
• Exploration of emerging therapies targeting cytokines, lymphocytes, and co-stimulatory molecules.
• Assessment of non-pharmacological interventions and lifestyle modifications in SLE management.

Main Results:

• Belimumab represents a significant advancement as the first approved biologic agent for SLE.
• Numerous novel therapies targeting specific immune pathways are under investigation.
• Growing evidence supports the importance of lifestyle modifications and a holistic approach in managing SLE and its comorbidities.

Conclusions:

• The treatment landscape for SLE is expanding with the introduction of targeted biologic therapies and promising novel agents.
• A holistic approach integrating pharmacological treatments, lifestyle adjustments, and supportive care is crucial for improving outcomes in SLE patients.
• Continued research into novel therapeutic targets is essential to further enhance the management and prognosis of systemic lupus erythematosus.